基于TGF-β1/Smads通路治疗心肌纤维化的研究进展
傅为武1 欧阳雅蓉1 黄彩依1 黄景伟1 吴聪1 秦晓君1 王庆高2
1.广西中医药大学研究生学院,广西南宁 530001;
2.广西中医药大学第一附属医院心血管科,广西南宁 530023
Research progress of treatment of myocardial fibrosis based on TGF-β1/Smads pathway
FU Weiwu1 OUYANG Yarong1 HUANG Caiyi1 HUANG Jingwei1 WU Cong1 QIN Xiaojun1 WANG Qinggao2
1.College of Graduate, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530001, China;
2.Department of Cardiology, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530023, China
摘要 心肌纤维化是全身多种疾病破坏心脏组织和结构的病理表现,可导致最终进展为心力衰竭。因此,抑制心肌纤维化,对于改善心脏结构、保护心脏功能意义重大。影响心肌纤维化的信号通路众多,但转化生长因子(TGF)-β1/Smads信号通路却是影响心肌纤维化的经典通路。近年来,对其抑制心肌纤维化的各种研究非常广泛,本文结合近年来国内外最新发表的相关文献,阐述中西医关于TGF-β1/Smads信号通路治疗心肌纤维化的最新进展,以期提供新的思路与方向。
关键词 :
转化生长因子-&beta ,
1/Smads通路 ,
心肌纤维化 ,
中西医 ,
研究进展
Abstract :Myocardial fibrosis is a pathological manifestation of heart tissue and structure destroyed by various diseases throughout the body, which can lead to heart failure. Therefore, inhibiting myocardial fibrosis is of great significance for improving heart structure and protecting heart function. Although there are many signal pathways that affect myocardial fibrosis, the transforming growth factor (TGF)-β1/Smads signaling pathway is a classic pathway that affects myocardial fibrosis. In recent years, various studies on its inhibition of myocardial fibrosis have been very extensive. This article combines the latest related documents published at home and abroad in recent years to explain the latest developments of TGF-β1/Smads signaling pathway in the treatment of myocardial fibrosis in Chinese and Western medicine, in order to provide new ideas and directions.
Key words :
Transforming growth factor-β1/Smads pathway
Myocardial fibrosis
Traditional Chinese and Western medicine
Research progress
基金资助: 广西科技厅重点研发计划项目(桂科AB171950 54);
广西中医药大学第一附属医院科研项目(2017XK03)。
通讯作者:
王庆高(1971-),男,博士,主任医师,主要从事临床心血管疾病治疗及研究。
作者简介 : 傅为武(1992-),男,广西中医药大学2018级中医内科学专业在读硕士研究生;研究方向:中西医结合防治心血管疾病。
[1] Ma Y,Zou H,Zhu XX,et al. Transforming growth factor β:apotential biomarker and therapeutic target of ventricular remodeling [J]. Oncotarget,2017,8(32):53780-53790.
[2] Jiang Y,Zhou X,Hu R,et al. TGF-β1-induced SMAD2/3/4 activation promotes RELM-β transcription to modulate the endothelium-mesenchymal transition in human endothelial cells [J]. Int J Biochem Cell Biol,2018,105:52-60.
[3] Lessard SJ,MacDonald TL,Pathak P,et al. JNK regulates muscle remodeling via myostatin/SMAD inhibition [J]. Nat Commun,2018,9(1):3030.
[4] Zhou N,Zhu Y,Zhang P,et al. Imperatorin derivative OW1 inhibits the upregulation of TGF-β and MMP-2 in renovascular hypertension-induced cardiac remodeling [J]. Exp Ther Med,2016,11(5):1748-1754.
[5] 方汉军,李锋华,许成,等.转化生长因子β1基因沉默脂肪干细胞移植对盐敏感性高血压大鼠心肌纤维化和心肌细胞的影响研究[J].实用心脑肺血管病杂志,2017,25(2):58-65.
[6] Meng Z,Li HY,Si CY,et al. Teng S. Asiatic acid inhibits cardiac fibrosis through Nrf2/HO-1 and TGF-β1/Smads signaling pathways in spontaneous hypertension rats [J]. Int Immunopharmacol,2019,74:105712.
[7] Hou J,Wang L,Hou J,et al. Peroxisome Proliferator-Activated Receptor Gamma Promotes Mesenchymal Stem Cells to Express Connexin43 via the Inhibition of TGF-β1/Smads Signaling in a Rat Model of Myocardial Infarction [J]. Stem Cell Rev Rep,2015,11(6):885-899.
[8] Yuan J,Chen H,Ge D,et al. Mir-21 Promotes Cardiac Fibrosis After Myocardial Infarction Via Targeting Smad7 [J].Cell Physiol Biochem,2017,42(6):2207-2219.
[9] Xiao X,Chang G,Liu J,et al. Simvastatin ameliorates ventricular remodeling via the TGF-β1 signaling pathway in rats following myocardial infarction [J]. Mol Med Rep,2016,13(6):5093-5101.
[10] Yu BT,Yu N,Wang Y,et al. Role of miR-133a in regulating TGF-β1 signaling pathway in myocardial fibrosis after acute myocardial infarction in rats [J]. Eur Rev Med Pharmacol Sci,2019,23(19):8588-8597.
[11] Chen Y,Li T,Gao Q,et al. MiR-1908 improves cardiac fibrosis after myocardial infarction by targeting TGF-β1 [J]. Eur Rev Med Pharmacol Sci,2018,22(7):2061-2069.
[12] Chen Z,Lu S,Xu M,et al. Role of miR-24,furin,and transforming growth factor-β1 signal pathway in fibrosis after cardiac infarction [J]. Med Sci Monit,2017,23:65-70.
[13] Zhang C,Zhou G,Chen Y,et al. Human umbilical cord mesenchymal stem cells alleviate interstitial fibrosis and cardiac dysfunction in a dilated cardiomyopathy rat model by inhibiting TNF-α and TGF-β1/ERK1/2 signaling pathways [J]. Mol Med Rep,2018,17(1):71-78.
[14] Sun Y,Ren J,Wu W. Effect of MiR-34a on hypertension-induced hypertrophic cardiomyopathy in rats via the TGF-β1/smads signaling pathway [J]. Minerva Med,2019,10.23736/S0026-4806.19.06192-5.
[15] 金智生,王东旭,张花治,等.红芪多糖对db/db小鼠糖尿病心肌病TGF-β1/Smads信号通路影响的实验研究[J].北京中医药大学报,2017,40(1):20-26.
[16] Lu M,Qin Q,Yao J,et al. Induction of LOX by TGF-β1/Smad/AP-1 signaling aggravates rat myocardial fibrosis and heart failure [J]. IUBMB Life,2019,71(11):1729-1739.
[17] Li X,Zhang ZL,Wang HF. Fusaric acid (FA) protects heart failure induced by isoproterenol (ISP) in mice through fibrosis prevention via TGF-β1/SMADs and PI3K/AKT signaling pathways [J]. Biomed Pharmacother,2017,93:130-145.
[18] Chen K,Chen W,Liu SL,et al. Epigallocatechingallate attenuates myocardial injury in a mouse model of heart failure through TGF-β1/Smad3 signaling pathway [J]. Mol Med Rep,2018,17(6):7652-7660.
[19] Zhang F,Dang Y,Li Y,et al. Cardiac Contractility Modulation Attenuate Myocardial Fibrosis by Inhibiting TGF-β1/Smad3 Signaling Pathway in a Rabbit Model of Chronic Heart Failure [J]. Cell Physiol Biochem,2016, 39(1):294-302.
[20] 刘畅,洪兰,金红花.五味子酚对心肌成纤维细胞增殖和转化生长因子β1及Ⅰ、Ⅲ型胶原蛋白表达的影响[J].中国现代医学杂志,2018,28(33):1-6.
[21] 乔璐,李博,李庆.氧化苦参碱对转化生长因子β1诱导大鼠心肌成纤维细胞增殖与分化的抑制作用[J].新中医,2018,50(11):6-9.
[22] 李庆敏,瞿武林,陈伯钧.铁皮石斛对缺血再灌注后心衰心气虚型大鼠心肌纤维化的抑制作用[J].中国实验方剂学杂志,2019,25(15):83-88.
[23] 张立双,张俊华,金鑫瑶,等.丹参酮ⅡA治疗心肌纤维化动物实验的系统评价[J].中药新药与临床药理,2018,29(5):595-602.
[24] 胡艳红,王雪,方靖漪,等.人参-三七-川芎提取物对糖尿病小鼠心肌纤维化的保护作用[J].中国实验方剂学杂志,2020,26(8):30-37.
[25] 陈纪烨,周国锋,王永成,等.桂枝汤桂芍不同比例配伍调节TGF-β(1)/Smads信号通路及慢性炎症改善盐敏感高血压大鼠心肌纤维化[J].中国实验方剂学杂志,2020, 26(1):50-58.
[26] 孟慧,王启新,卢文吉,等.保元汤调控AT1/P38 MAPK/TGF-β途径改善心肌纤维化防治心力衰竭的机制研究[J].中华中医药杂志,2019,34(5):2292-2297.
[27] 王健,李芳,周晓露,等.加味真武汤辨治慢性心力衰竭阳气亏虚证心肌纤维化的临床观察[J].中国实验方剂学杂志,2018,24(11):173-178.
[1]
王庚新1 张春玲2 唐丽莎1 罗开中1 李桃1 张云1. 糖尿病足溃疡愈合相关信号通路的研究进展 [J]. 中国医药导报, 2021, 18(6): 46-49.
[2]
张宇1 薛勤梅2. TGF-β1和CTGF与输卵管炎性阻塞性不孕输卵管纤维化相关性的研究进展 [J]. 中国医药导报, 2021, 18(6): 50-53.
[3]
抑郁障碍中西医整合诊治专家共识组 中国民族医药学会神志病分会. 抑郁障碍中西医整合专家共识 [J]. 中国医药导报, 2021, 18(6): 4-12.
[4]
方圣杰1 朱立国1 魏戌2 孙凯1 王旭1 师彬3 杨少锋4. 颈痛颗粒治疗神经根型颈椎病的研究进展 [J]. 中国医药导报, 2021, 18(3): 48-51.
[5]
祁永华 孙晖 张宁. 中药辅助治疗化疗后骨髓抑制的实验研究进展 [J]. 中国医药导报, 2020, 17(9): 21-24.
[6]
陈俊名1 岳辰2 范亚楠2 何沛霖1 王会超2 刘又文2. 股骨头坏死动物造模研究进展 [J]. 中国医药导报, 2020, 17(9): 25-28.
[7]
王素1 李一平1 谢宁2. Wnt/LRP6信号通路对阿尔茨海默病突触功能影响的研究进展 [J]. 中国医药导报, 2020, 17(8): 33-35,47.
[8]
胡枝敏 凌望 吴美平. 支架植入后抑制平滑肌细胞过度增殖的研究进展 [J]. 中国医药导报, 2020, 17(7): 27-30.
[9]
吕凯峰 张伟 陈宏. 中医药治疗小儿肺炎临床研究进展 [J]. 中国医药导报, 2020, 17(6): 37-39.
[10]
王怡茹 张一凡 刘萍. 免疫细胞参与动脉粥样硬化炎症反应的研究进展 [J]. 中国医药导报, 2020, 17(35): 46-48,52.
[11]
董文芳1* 王文妤2* 林洁1 邬宇芬1 袁姝华1 张皓1 张斌2. 杏贝止咳颗粒辅助治疗儿童急性支气管炎的效果 [J]. 中国医药导报, 2020, 17(34): 153-156,180.
[12]
葛新颖1,2 袁源见2 吕丹3▲. 中医药健康养老服务研究进展 [J]. 中国医药导报, 2020, 17(33): 190-193.
[13]
宋净洋1 车祥源1 邢红霞2. 帕金森病的非人灵长类动物模型研究进展 [J]. 中国医药导报, 2020, 17(32): 44-47.
[14]
田万朋 李柳宁 刘伟胜. 刘伟胜教授辨治食管癌的经验 [J]. 中国医药导报, 2020, 17(32): 124-127.
[15]
封继宏1 张珊珊2 毕明达2. 中医药干预慢性阻塞性肺疾病相关信号通路传导的研究进展 [J]. 中国医药导报, 2020, 17(30): 37-40.